Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5983_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •About the Editor
- •Contents
- •Contributors
- •1.1.4 Components of niosome
- •1.1.5 Factors affecting niosomes
- •Preface
- •Abstract
- •1.1 Introduction
- •1.1.1 Why niosome?
- •1.1.2 Advantages of niosome
- •1.1.3 Structure of niosome
- •1.2 Applications of niosome
- •1.2.2 Niosomes for the delivery of therapeutics
- •1.2.3 Niosomes in biomedical applications
- •1.3 Conclusions and future prospects
- •Keywords
- •References
- •Abstract
- •2.1 Introduction
- •2.2 Conclusions
- •Acknowledgments
- •Keywords
- •References
- •Abstract
- •3.1 Introduction
- •3.2.1 Parameters involved in electrospinning process
- •3.2.2 Biomaterials for electrospinning
- •3.3 Electrospun nanofibers as drug delivery systems
- •3.3.1 Blending electrospinning
- •3.3.2 Emulsion electrospinning
- •3.3.3 Coaxial electrospinning
- •3.3.4 Surface modifications
- •3.4 Electrospun nanofibers for tissue engineering
- •3.4.1 Electrospun nanofibers for hard tissue engineering
- •3.5 Cancer diagnosis and therapy
- •3.6 Concluding remarks and future perspectives
- •Keywords
- •References
- •4. Natural Biocarriers for Brain Targeting
- •Abstract
- •4.1 Introduction
- •4.1.1 Central nervous system
- •4.2 Biocarriers
- •4.2.1 Carbohydrates carriers
- •4.2.2 Protein carriers
- •4.2.3 Exosomes
- •4.3 Conclusions and perspectives
- •Keywords
- •References
- •Abstract
- •5.1 Introduction
- •5.2 Synthesis of graphene family nanomaterials
- •5.2.1 Graphene synthesis
- •5.2.2 GO and rGO Syntheses
- •5.2.3 GQd synthesis
- •5.4 Drug delivery and biomedical applications
- •5.4.1 Drug delivery
- •5.4.2 Gene delivery
- •5.4.3 Bioimaging
- •5.4.4 Photothermal therapy
- •5.4.5 Tissue engineering
- •5.5 Summary and future prospect
- •Keywords
- •References
- •6. Nanotechnology in Gene Delivery
- •Abstract
- •6.1 Introduction
- •6.2 Gene delivery
- •6.3 Nanotechnology in gene delivery
- •Keywords
- •References
- •Abstract
- •7.1 Introduction
- •7.2 Additive manufacturing in pharmacology
- •7.2.1 Extrusion-based 3D printing techniques
- •7.2.2 Stereolithography
- •7.2.3 Selective laser sintering
- •7.2.4 Binder jet printing
- •7.3 Most common polymers
- •7.3.1 Natural polymers
- •7.3.2 Synthetic polymers
- •7.3.2.5 Polyvinylpyrrolidone
- •7.4 Common 3D-printed dosage forms
- •7.4.1 Scaffolds
- •7.4.2 Tablets
- •Keywords
- •References
- •7.4.3 Microneedles
- •7.4.4 Capsule
- •7.4.5 Films
- •7.5 Main factors in drug delivery
- •7.5.1 Nature of polymers
- •7.5.2 Matrix permeability
- •7.5.3 Polymer blends
- •7.5.4 Specific surface area
- •7.5.5 Infill density and patterns
- •7.5.6 Pores
- •7.5.7 Cross-linking
- •7.5.8 Coating
- •7.5.9 Core/shell and multicompartment
- •7.6 Final considerations and future perspectives
- •Abstract
- •8.1 Introduction
- •8.2.1 Polymer solution concentration and viscosity
- •8.2.2 Molecular weight of polymer
- •8.2.3 Surface tension
- •8.2.4 Electrical conductivity
- •8.2.5 Applied voltage
- •8.2.6 Feed rate/flow rate
- •8.2.7 Temperature and humidity
- •8.3 Method of preparation for nanofibers
- •8.3.1 Electrospinning
- •8.3.2 Self-assembly
- •8.3.3 Phase separation
- •8.3.4 Drawing of nanofibers
- •8.3.5 Template synthesis
- •8.4 Biomedical applications of nanofibers
- •8.4.1 Wound dressing
- •8.4.2 Tissue engineering
- •8.4.3 In cancer therapy
- •8.4.4 Miscellaneous
- •8.5 Drug delivery application
- •8.5.1 Antihypertensive drug
- •8.5.2 Antimicrobial drug
- •8.5.3 Growth hormone
- •8.5.4 Miscellaneous
- •8.6 Conclusion
- •Keywords
- •References
- •Abstract
- •9.1 Introduction
- •9.2 Tissue engineering
- •9.3 Nanotechnology
- •9.4 Polymeric scaffolds in tissue engineering
- •9.5 Challenges
- •Keywords
- •References
- •Abstract
- •10.1 Introduction
- •10.2 Ideal properties of bioceramics
- •10.2.1 Mechanical property
- •10.2.2 Porosity, pore size, and shape
- •10.2.3 Biocompatibility and biodegradability
- •10.2.4 Osteoconductivity and osseointegrity
- •10.3 Bioceramics in orthopedic applications
- •10.4 Bioceramics in maxillofacial surgery
- •10.5 Bioceramic in drug delivery applications
- •10.6 Doped bioceramic in biomedical application
- •10.7 Conclusions
- •10.8 Future direction
- •Acknowledgments
- •Keywords
- •References
- •Index

78
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
-
linking (Koosha et al., 2021).
3.3.3 COAXIAL ELECTROSPINNING
An initial burst release may be occurred in simple blending and emulsion
overcome this burst release, postprocessing treatments such as cross-linking
as reduced biocompatibility (Han et al., 2020). Coaxial electrospinning is
in vitro drug release
period (Gong et al., 2019).
3.3.4 SURFACE MODIFICATIONS

Electrospun Technology for Drug Delivery and Biomedical Applications
79
-
-
-
through chemical bonding can decrease the initial burst release and maintain
3.4 ELECTROSPUN NANOFIBERS FOR TISSUE ENGINEERING
-
be electrospun that can be reabsorbed by the human body. Altogether, these
3.4.1 ELECTROSPUN NANOFIBERS FOR HARD TISSUE ENGINEERING

80
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
al., 2021). Natural bone has unique mechanical qualities due to its unique
-
-
pore patterns and striving to emulate the three-dimensional (3D) electrospin-
-
-

Electrospun Technology for Drug Delivery and Biomedical Applications
81
et al., 2007). For instance, numerous scientists have developed electrospun
-
techniques such as electrospraying and coaxial electrospinning (Xie et al.,
-
structures (Chahal et al., 2019).
3.4.2 ELECTROSPUN NANOFIBROUS SCAFFOLDS FOR SOFT TISSUE
HEALING
tooth, and cartilage. Hence, skin, musculoskeletal, adipose, cardiovascular,
vasculature, neural, lung, liver, kidney, gastrointestinal, and ocular tissues
main problem is that they can be easily absorbed and rapidly lost in the
al., 2014). In addition, donor-site allogeneic response and morbidity limit
approach, tissue engineering has been employed to develop potent substi-
angiogenesis, avoiding scarring, and consequently restoring the pristine
changing the electrospinning parameters and the collection process, various

82
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
-
provide topographical cues and tropism by modulating the gradient structure
nerves and central nerves), heart, blood vessels, gastrointestinal, and cornea
-
-
-
3.5 CANCER DIAGNOSIS AND THERAPY
-

Electrospun Technology for Drug Delivery and Biomedical Applications
83
TABLE 3.1
Composition Tissues Cell type Outcomes Ref
Hard tissue engineering
Bone BMSCs (Liu et al., 2022)
PVP, ethylcellulose, Au NPs Bone hBMSCs
osteogenic genes and promoted bone regeneration.
(Huang et al., 2021)
Bone hASCs Improved cell adhesion and osteogenic gene expression. (Ahmad et al.,
2018)
inductive peptide H1
Bone hiPS-MSCs
(Xu et al., 2019)
sodium alginate
Periosteum
osteoblast cells
Facilitated osteoblast attachment and upregulated the early expression
Dentin hDPCs
(Anselmi et al.,
2022)
Nano-hydroxyapatite into
PCL
Dentin hDPCs (Mendes Soares et
al., 2022)
Soft tissue engineering
Cartilage hASCs
PLA into lignin Cartilage BMSCs
(Liang et al., 2022)
bone
MSC
2017)
oxide nanoparticles and CPP
tendon
Human tenocytes Improved the tendon ECM restoration and prevented bacterial
adhesion.
(Bianchi et al.,
2023)
GO-PLGA
tendon
BMSC
generation, and improved collagen arrangement and biomechanical
properties.
(Su et al., 2019)

84
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
Composition Tissues Cell type Outcomes Ref
GelMA Skin Human dermal
HUVECs
-
(Sun et al., 2017)
polystyrene and poly (4-VP)
Skin (Venault et al.,
2020)
Skin RBC and L929
collagen deposition, and angiogenesis.
(He et al., 2020)
Skin hMSCs
(Ahmad et al.,
2018)
Nerve PC12 cells and DRG
cells
Induced neurite alignment and extension. (Wang et al., 2019)
Neurite PC12 cells
visible-light stimulation.
Neurite Neural progenitor cell
(Chen et al., 2019)
Neurite
cells
Induced pro-angiogenic characteristics. Promoted morphological and
(Qian et al., 2018)
Keratin associated PCL Vascular -
plastin time.
(Li et al., 2016)
Vascular HUVECs Supported endothelial cell viability and adhesion.
Cardiac
deteriorated ventricular remodeling restrained by nanopatch.
(Chen et al., 2018)
TABLE 3.1 (Continued)

Electrospun Technology for Drug Delivery and Biomedical Applications
85
Composition Tissues Cell type Outcomes Ref
Cardiac Rat cardiac cells
muscle.
(Fleischer et al.,
2017)
Liver Primary human
hepatocytes
Enhanced primary human hepatocyte synthetic activity.
PES
Liver Human endometrial
stem cells
2017)
Kidney
human conditionally
-
(Jansen et al., 2019)
Esophagus Primary human
ultimate tensile strength as the native esophagus.
(Wu et al., 2018)
Polyurethane Esophagus hAMSCs (Park et al., 2021)
PLGA Skeletal
muscle
Murine myoblast cells
(C2C12)
(Narayanan et al.,
2020)
Skeletal
muscle
Rat muscle precursor
cells
(Patel et al., 2020)
Abbreviations
-
TABLE 3.1
(Continued)

86
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
FIGURE 3.3
Source
-

Electrospun Technology for Drug Delivery and Biomedical Applications
87
an implant into the postoperative tumor cavity, to prevent tumor recur-
Cavo et al., 2020). It has also been mentioned that these matrices have
demonstrated promising potential as transdermal drug delivery systems to
-
-
responsive behavior enhance the drug delivery capability in the response
cancers malignant tumors. Based on this, biosensors are regarded to have a
-
-
as a proper substrate to capture and detect cancer biomarkers and circulating
Соседние файлы в папке Библиотека им академика М.И. Перельмана
